Population pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide metabolite in patients with autoimmune glomerulonephritis.

Veatriki N IliopoulouGeorgia CharkoftakiJennifer C CooperAristides DokoumetzidisMelanie S Joy

Published in: The Journal of pharmacy and pharmacology (2022)

A population pharmacokinetic model was developed for CY and 4-OH in patients with autoimmune glomerulonephritis. Simulations using various dose regimens allow for informed dosing before the initiation of therapy.

Keyphrases

multiple sclerosis
low dose
molecular dynamics
stem cells